We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.
Accolade (ACCD)
+16%
Shares of Accolade traded up over 16% on Thursday, tracking the broad market rally. Earlier this week, the healthcare benefits management company showcased its personalized approach to insurance plans to the conference of “Advocating for Health Insurance Providers” (AHIP).
Shares of Ginkgo Bioworks traded up 18% with Thursday’s broad market rally. We maintain our positive thesis on the Boston-based synthetic biology company and note that it recently acquired Bitome––a company specializing in real-time metabolite measurement––and reached a new research milestone in its collaboration with Cronos Group.
Shares of 908 Devices appreciated 18% alongside Thursday’s broad market rally, just two weeks after the company showcased to the American Society of Mass Spectrometry its protocols for expediting mass spectrometry procedures. 908 Devices is a life sciences tools company that miniaturizes mass spectrometry in order to decentralize chemical and biomolecular analysis.
Shares of Veracyte traded up over 16% during Thursday’s broad market rally, just days after the company demonstrated the efficacy of its Afirma Genomic Sequencing Classifier to improve the accuracy of thyroid cancer diagnosis. The pioneer in gene expression-based prognostic testing is one of the most vertically-integrated molecular testing companies on the market, in our view, and its decentralized testing portfolio (assays and instruments) should position the company to win significant share within and beyond the US.
